Eden Research plc (AIM: EDEN), the AIM listed company that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, is pleased to announce that its associate company, TerpeneTech Limited ("TerpeneTech"), has received regulatory clearance to sell its head-lice product in the European Economic Area ("EEA").
Sales of the head-lice product into the distribution channel are expected to begin before the end of 2018 in the UK, where TerpeneTech's distribution channel partner has already been established, with commercial launch at the beginning of 2019. Sales will commence in other countries in the EEA once arrangements with additional distribution partners have been finalised. This is expected to take place during 2019.
Eden will supply a concentrate of encapsulated active ingredients (based upon Eden's microencapsulation technology) to TerpeneTech, who will then formulate the finished product for initial sale by its distribution partner into the UK retail market.
Sean Smith, Chief Executive Officer of Eden, said: "The development of this head-lice product has been in progress for approximately three years and it is good to see it now being commercialised.
The launch of any consumer product into a regulated market, such as the head-lice treatment products market, is significantly more complicated, time consuming and costly than launching products into unregulated markets. Therefore, we are pleased with the progress that TerpeneTech has made in only three years since it was granted a licence to use Eden's microencapsulation technology for head-lice treatment formulations.
The head-lice markets, globally, tend to be quite fragmented, and so we feel that the approach being taken by TerpeneTech's distribution partner to include the under-served discount-retail market is sensible."
Antoine Biron, Director of TerpeneTech, said: "Our head-lice treatment product has performed very well in clinical trials where it has been tested against leading, competitive products. We believe that the product will be well-received by consumers due to the product's naturally-derived active ingredients, ease of use, safety and efficacy.
We look forward to the UK product launch being the first of several in the EEA and eventually the US for both the head-lice product and other products, such as our naturally-derived under-arm deodorant, subject to any requisite regulatory approval."
Eden tweeted this:
We are very pleased to work with @SumiAgroFrance to help accelerate innovation in #BioControle in France and elsewhere. #sustainableagriculture #sustainablechemistry #sustaine
But it is all becoming meaningless as it does not mean bigger sales for Eden, bigger profits or anything at all to benefit the shareholders.
"We are delighted that Cedroz and Eden partner Eastman have been short-listed for “Best New Biological Product” at this year’s Agrow Awards! Eastman is Eden’s exclusive partner for the bionematicide B2Y in nearly 30 countries."
Why don't they RNS these things?
I wonder what the 3 patents were?
https://www.msn.com/en-gb/news/offbeat/why-plant-based-mosquito-repellents-are-so-hard-to-design/ar-BBN6RK9?ocid=spartanntp
Bar everything, I suspect.
Peak sales season and not a peep from the company.
What don't they get?
Or have we backed a company that is good on paper but not in reality?
Great product but can't het the message across to the buyers?
Cheaper and just as good other options available?
They probably told people how good it was...
There has been some decent wet, warm and humid weather over Europe recently but is Eden shouting about their product flying off the shelves?
No, though as we know, Eden doesn't do good news stories. (or bad news stories, or....)
I'm still wondering if we really know the level of competition in the eco/bio world.
https://agrow.agribusinessintelligence.informa.com/AG029893/Uruguay-sets-MRLs-per-EUUS-standards
I'm not signing up to read the whole article.